Search

Displaying results 1661 - 1670 of 10000 in total
  1. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected … Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label].

  2. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    Etripamil is a nondihydropyridine, L-type calcium channel blocker.[A275238, L54728] It is a fast-acting drug with a short duration of action. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  3. Drug

    Tienilic acid

    go.drugbank.com/drugs/DB04831
    ApprovedWithdrawn

    Tienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. … It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982)

  4. Drug

    Picric acid

    go.drugbank.com/drugs/DB03651
    Approved

    Used as antiseptic, astringent, and stimulant for epitheliazation.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors.

  6. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g.

  7. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. … [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.

  8. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. … It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  9. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis. … Loteprednol Etabonate (LE) is a topical corticoid anti-inflammatory.

  10. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295]. … Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846].